PT - JOURNAL ARTICLE AU - Delgado Sanchis, Juan A. AU - Signol, François AU - Perez-Cortes, Juan-Carlos AU - García-López, Eva M. AU - Mena-Mollá, Salvador AU - Carbonell-Monleón, Nieves AU - Rodríguez-Gimillo, María AU - García-Giménez, José Luis TI - A machine learning based predictive model for the diagnosis of sepsis AID - 10.1101/2022.04.29.22274361 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.29.22274361 4099 - http://medrxiv.org/content/early/2022/05/01/2022.04.29.22274361.short 4100 - http://medrxiv.org/content/early/2022/05/01/2022.04.29.22274361.full AB - The early recognition and treatment of sepsis is essential to increase the probability of survival of the patient. Sepsis is a complex and heterogeneous syndrome influenced by the site of infection, causative microorganisms, acute organ dysfunctions and co-morbidities. So, early diagnosis is a challenge in which complex physiologic, metabolic, biochemical markers and clinical signs must be evaluated simultaneously for a reliable and early identification of sepsis. In this paper, a list of relevant variables involved in sepsis diagnosis is provided. Furthermore, to help answering the question of whether a patient is suffering from sepsis when entering the emergency room, a model based on the machine learning gradient boosting algorithm is proposed. Using three histones H2B, H3, H4 and the activated protein C together with other variables a gradient boosting classifier was trained and evaluated with cross validation. Results show that the model can achieve up to a 97% mean per-class accuracy.Competing Interest StatementJosé Luis García-Giménez (JLGG) is inventor of a patent related with the use of circulating histones for the early diagnosis and prognosis of sepsis. Co-owners of this patent are the Consortim Center for Biomedical Network Research, Biomedical Research Institute INCLIVA and University of Valencia. The patent has been licensed to EpiDisease S.L. a Spin-Off from the CIBER-ISCIII. Other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Funding StatementThis research was funded by grants PI19/00994 funded by AES (ISCIII) co-financed by the European Regional Development Fund (ERDF) and Agencia Valenciana de Innovación (INNVA1/2020/85) and Fundación Mutua Madrileña (AP174352020).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Hospital Universitario Clı́nico de Valencia (HCUV) gave ethical approval for this work with registry number 2019/051.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.